Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancerErin M Coffee, Anthony C Faber, Jatin Roper, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Genome Biology|June 5, 2008
A mouse plasma peptide atlas as a resource for disease proteomicsQing Zhang, Rajasree Menon, Eric W Deutsch, et al.
Nature|October 5, 2012
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growthSergei I Grivennikov, Kepeng Wang, Daniel Mucida, et al.
The Lancet. Gastroenterology & Hepatology|July 24, 2025
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trialSilvio Danese, Jessica R Allegretti, Stefan Schreiber, et al.
Nature Medicine|May 27, 2014
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid cultureXingnan Li, Lincoln Nadauld, Akifumi Ootani, et al.
Inflammatory Bowel Diseases|August 24, 2021
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative ColitisMina Hassan-Zahraee, Zhan Ye, Li Xi, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|June 6, 2022
Prognostic implication of the neoadjuvant rectal score and other biomarkers of clinical outcome in Hong Kong Chinese patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapyS S K Ho, S S F Hon, E Hung, et al.
Cancer Cell|December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsRyan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Pageof 7